DUBLIN - June 24, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 ...

Medtronic plc, the global leader in medical technology, announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes seven ...

Medtronic has issued a second alert letter to patients regarding shortened battery life of the MiniMed 600 and 700 series insulin pumps. The affected products include the MiniMed 630G, 670G, 770G, and ...

Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.

In-home hybrid closed-loop system MiniMed from Medtronic can help kids with Type 1 diabetes improve their glycemic outcomes, according to a recent abstract that was presented at the meeting of ...

Medtronic plc MDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.